Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|July 10, 2015
The Legacy of HIPAA Legislation
Author(s)Davy James, Managing Editor
Ron Lanton III, Esq, president of True North Political Solutions, LLC, discusses how specialty pharmacy has been affected by HIPAA laws.
Advertisement
Ron Lanton III, Esq, president of True North Political Solutions, LLC, discusses how specialty pharmacy has been affected by HIPAA laws.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
2
Ambulatory Pharmacists Convene in Boston at NEIAP's 2026 Annual Forum
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
From Reactive to Proactive: AI's Role in Modern Pharmacy Safety
5